IMO there are 3 reasons to anticipate a strong and positive...

IMO there are 3 reasons to anticipate a strong and positive reaction to the NASDAQ listing.

Firstly, the calibre of Roth Capital. Have a look at the recent dual listings they’ve championed such as IMU and LKE. This a group that truly gets behind companies and their returns are 5 times or more. We don’t have institutions like this in Australia, they don’t exist. There are also very few Aussie companies that are dual listed on a main US exchange like the NASDAQ. Most of the comparisons posters are discussing are only OTC listed and that’s like comparing a Toyota Corolla with a Bentley Continental GT.

Secondly, all the similar NASDAQ listed companies in our sector like Compass Pathways, Mind Medicine and Cara Therapeutics trade at significantly higher valuations. Previously GW Pharma was in that list too and they were acquired for US$7.4 billion. In other words IHL will look substantially undervalued compared to its peers.

Thirdly, we are moving into a period of significant news flow on clinical trials. For instance, the OSA results will likely occur after the NASDAQ listing. What’s IHL going to be trading at if those results are positive?

We are talking about a multi billion dollar opportunity and the day to day price movements are of no consequence IMO.